Amyris' commercialization of B2C product potentially improves the company's profit margin

Over the past few years, Amyris has tightened its clutch on the lucrative consumer product market. After selling its fermentation-based squalene (Neossance) as a raw ingredient for third-party cosmetic manufacturers for the past year, the company officially launched its consumer-facing squalene-b...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research

Givaudan bets big on synthetic biology for specialty ingredients production

News Commentary | September 09, 2021

Givaudan and Manus Bio recently announced that they have achieved key scale‑up milestones in developing a food and beverage ingredient. While details on the target ingredient are scarce, Givaudan is looking to commercialize this ingredient by the end of this year. Interestingly, Givaudan also ... Not part of subscription

Momentum surrounding biosurfactants continues as Evonik invests in its first industrial-scale production plant for rhamnolipids

News Commentary | January 27, 2022

Evonik's long‑planned facility will supply biosurfactants to its partner, Unilever, which launched a dish soap with rhamnolipids in 2019. Although rhamnolipids have appealing sustainability and performance properties, commercialization has been limited by high costs, with rhamnolipids previously ... Not part of subscription

Manus Bio

Company Profile | March 17, 2022

Develops specialty ingredients through microbial fermentation; over the past two years, the company has focused on developing its integrated technology platform, BioAssemblyLine, which encompasses metabolic engineering, protein engineering, and systems biology approaches to engineer microbes that... Not part of subscription